SAB4503373
Anti-TEAD2 antibody produced in rabbit
affinity isolated antibody
Synonym(s):
TEA domain family member 2, TEAD-2
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 49 kDa
species reactivity
human, mouse
concentration
~1 mg/mL
technique(s)
ELISA: 1:5000
immunofluorescence: 1:100-1:500
immunohistochemistry: 1:50-1:100
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... TEAD2(8463)
General description
TEA domain transcription factor 2 (TEAD2) belongs to the TEAD family. TEAD2 gene is located on human chromosome 19q13.3 Anti-TEAD2 antibody detects endogenous levels of total TEAD2 protein.
Immunogen
The antiserum was produced against synthesized peptide derived from human TEAD2.
Immunogen Range: 71-120
Immunogen Range: 71-120
Application
Anti-TEAD2 antibody produced in rabbit has been used in western blotting.
Biochem/physiol Actions
TEA domain transcription factor 2 (TEAD2) plays a regulatory role in cell stemness. It modulates the expression of several genes. TEAD2 participates in the maintenance of cell survival. It is essential during neural development. TEAD2 might be a new therapeutic target and a predictive indicator of hepatocellular carcinoma (HCC).
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yanli Wang et al.
Molecular medicine reports, 20(4), 3519-3526 (2019-09-06)
Cisplatin has been widely used as a conventional treatment for patients with non‑small cell lung cancer (NSCLC). However, primary and acquired cisplatin resistances are frequently developed during the treatment of patients with NSCLC, leading to an increased mortality rate. Accumulating
Kotaro J Kaneko et al.
Genesis (New York, N.Y. : 2000), 45(9), 577-587 (2007-09-18)
TEAD2, one of the first transcription factors expressed at the beginning of mammalian development, appears to be required during neural development. For example, Tead2 expression is greatest in the dorsal neural crest where it appears to regulate expression of Pax3
Localization of human transcription factor TEF-4 and TEF-5 (TEAD2, TEAD3) genes to chromosomes 19q13.3 and 6p21.2 using fluorescence in situ hybridization and radiation hybrid analysis.
P Jacquemin et al.
Genomics, 55(1), 127-129 (1999-01-16)
Jong Seok Joo et al.
Oncology reports, 43(6), 1785-1796 (2020-04-24)
TEA Domain Transcription Factors (TEADs) are important in development and serve essential roles in tumorigenesis; however, the role of TEAD2 expression in hepatocellular carcinoma (HCC) has not been widely examined. The present study was conducted to investigate the expression status
Paula González-Alonso et al.
Cancers, 12(5) (2020-05-06)
Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired resistance to trastuzumab. We established an acquired trastuzumab-resistant
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service